AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10645749 — intervention group
Group type: COMPARATOR
Intervention: Control and task-performance goals
Number of subjects: 104
Study 10645749 — intervention group
Group type: COMPARATOR
Intervention: Conversation strategies and goals in mixed-gender dyads
Number of subjects: 104
Study 9487617 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthopedic hippotherapy
Number of subjects: 0
Study 12959285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 24
Study 12959285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 24
Study 12959285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 12959285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (both doses)
Number of subjects: 24
Study 3641693 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (400 mg/d)
Number of subjects: 14
Study 3641693 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestrinone (5 mg/week)
Number of subjects: 14
Study 30348346 — intervention group
Group type: EXPERIMENTAL
Intervention: SRS‐22 + BAS (n = 24)
Number of subjects: 45
Study 30348346 — intervention group
Group type: COMPARATOR
Intervention: BAS only (n = 21)
Number of subjects: 45
Study 27397626 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh blastocyst transfer
Number of subjects: 134
Study 27397626 — intervention group
Group type: COMPARATOR
Intervention: Thawed bipronuclear oocytes transfer
Number of subjects: 134
Study 24849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (900 μg subcutaneously twice daily for 7 days)
Number of subjects: 300
Study 24849084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 24849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (in pancreaticoduodenectomy subgroup)
Number of subjects: 300
Study 24849084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in pancreaticoduodenectomy subgroup)
Number of subjects: 300
Study 24849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (in distal pancreatectomy subgroup)
Number of subjects: 300
Study 24849084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in distal pancreatectomy subgroup)
Number of subjects: 300
Study 24849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (in patients with dilated pancreatic duct)
Number of subjects: 300
Study 24849084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with dilated pancreatic duct)
Number of subjects: 300
Study 24849084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide (in patients with nondilated pancreatic duct)
Number of subjects: 300
Study 24849084 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with nondilated pancreatic duct)
Number of subjects: 300
Study 22173217 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine
Number of subjects: 60
Study 22173217 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 21246843 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with oral administration of Felodipine (group A)
Number of subjects: 60
Study 21246843 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Felodipine only (group B)
Number of subjects: 60
Study 18794650 — intervention group
Group type: EXPERIMENTAL
Intervention: Add-on of aripiprazole on a current regimen, wait for 4 weeks, and tapering of prior antipsychotics
Number of subjects: 53
Study 18794650 — intervention group
Group type: COMPARATOR
Intervention: Add-on of aripiprazole and simultaneous tapering of prior antipsychotics
Number of subjects: 53
Study 15878318 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 20 mug (TPTD20)
Number of subjects: 558
Study 15878318 — intervention group
Group type: EXPERIMENTAL
Intervention: teriparatide 40 mug (TPTD40)
Number of subjects: 558
Study 15878318 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 558
Study 11843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult‐II (H‐II) screening followed by colonoscopy
Number of subjects: 30967
Study 11843044 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoccult‐II (H‐II) screening
Number of subjects: 30967
Study 10073816 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative clinical algorithm for cardiac risk stratification
Number of subjects: 320
Study 10073816 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole thallium‐201 scintigraphy
Number of subjects: 320
Study 10073816 — intervention group
Group type: EXPERIMENTAL
Intervention: Presurgical myocardial revascularization
Number of subjects: 320
Study 10073816 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular surgery with perioperative intensive care treatment
Number of subjects: 320
Study 7479623 — intervention group
Group type: EXPERIMENTAL
Intervention: On-sale outlets
Number of subjects: 887
Study 7479623 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-sale outlets
Number of subjects: 887
Study 2254672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium 500 (1.5 g, 3 capsules/day)
Number of subjects: 225
Study 2254672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study 2254672 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxium 500
Number of subjects: 225
Study 7016973 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicyclomine hydrochloride 40 mg 4 times daily
Number of subjects: 0
Study 7016973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31562118 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 655
Study 31562118 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 655
Study 29697595 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 230
Study 29697595 — intervention group
Group type: COMPARATOR
Intervention: Testing as usual
Number of subjects: 230
Study 26986563 — intervention group
Group type: EXPERIMENTAL
Intervention: Institutional delivery service utilization
Number of subjects: 957
Study 26986563 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of institutional delivery
Number of subjects: 957
Study 26986563 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal care service
Number of subjects: 957
Study 24833692 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based information booklet including overdetection, breast cancer mortality reduction and false positives
Number of subjects: 970
Study 24833692 — intervention group
Group type: COMPARATOR
Intervention: Control information booklet (including mortality reduction and false positives only)
Number of subjects: 970
Study 24833692 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based information booklet
Number of subjects: 970
Study 24833692 — intervention group
Group type: COMPARATOR
Intervention: Control information booklet
Number of subjects: 970
Study 22956531 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Marsh model
Number of subjects: 66
Study 22956531 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol administered to reach and maintain a predetermined propofol effect-site concentration (Ce) based on the Schnider model
Number of subjects: 66
Study 20491772 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser (EL)
Number of subjects: 13
Study 20491772 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol propionate (CP)
Number of subjects: 13
Study 18797455 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIRI (capecitabine plus irinotecan)
Number of subjects: 267
Study 18797455 — intervention group
Group type: COMPARATOR
Intervention: CAP (capecitabine single agent)
Number of subjects: 267
Study 18797455 — intervention group
Group type: EXPERIMENTAL
Intervention: CAPIRI (for Val-allele carriers)
Number of subjects: 267
Study 18797455 — intervention group
Group type: COMPARATOR
Intervention: CAPIRI and CAP (Ile/Ile genotype)
Number of subjects: 267
Study 16042878 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg entecavir
Number of subjects: 212
Study 16042878 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg entecavir
Number of subjects: 212
Study 16042878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 11819181 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 500 mg po bid
Number of subjects: 18
Study 10574107 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg (100 ml) given by slow intravenous infusion 90-60 minutes before operation
Number of subjects: 20
Study 10574107 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (control group)
Number of subjects: 20
Study 9051513 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation using a forceps
Number of subjects: 100
Study 9051513 — intervention group
Group type: COMPARATOR
Intervention: Implantation using an injector
Number of subjects: 100
Study 1649422 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy (40 patients)
Number of subjects: 60
Study 1649422 — intervention group
Group type: COMPARATOR
Intervention: Immunomodulating therapy with Sintomodulin (20 patients)
Number of subjects: 60
Study 6842340 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 49
Study 6842340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 31781298 — intervention group
Group type: EXPERIMENTAL
Intervention: miR‐1, miR‐133a, and miR‐499
Number of subjects: 122
Study 31781298 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP
Number of subjects: 122
Study 31781298 — intervention group
Group type: EXPERIMENTAL
Intervention: hsTnT
Number of subjects: 122
Study 31781298 — intervention group
Group type: EXPERIMENTAL
Intervention: LVEF
Number of subjects: 122
Study 29426362 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice containing three kinds of bactericidal ingredients
Number of subjects: 30
Study 29426362 — intervention group
Group type: EXPERIMENTAL
Intervention: Test dentifrice
Number of subjects: 30
Study 26827977 — intervention group
Group type: EXPERIMENTAL
Intervention: Elipar LED unit, cured for 10 seconds
Number of subjects: 40
Study 26827977 — intervention group
Group type: COMPARATOR
Intervention: VALO LED unit, cured for 3 seconds
Number of subjects: 40
Study 26827977 — intervention group
Group type: EXPERIMENTAL
Intervention: In-vitro bond strengths for Elipar LED unit
Number of subjects: 40
Study 26827977 — intervention group
Group type: COMPARATOR
Intervention: In-vitro bond strengths for VALO LED unit
Number of subjects: 40
Study 25497747 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (500mcg/kg bolus followed by 100mcg/kg/min infusion)
Number of subjects: 60
Study 25497747 — intervention group
Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 60
Study 22435980 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy massage using lavender oil
Number of subjects: 40
Study 22435980 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 20353312 — intervention group
Group type: EXPERIMENTAL
Intervention: MPH-ER
Number of subjects: 363
Study 20353312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 363
Study 18517090 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Treatment (ET)
Number of subjects: 281
Study 18517090 — intervention group
Group type: COMPARATOR
Intervention: Minimal Treatment (MT)
Number of subjects: 281
Study 16014055 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels
Number of subjects: 1560
Study 12757209 — intervention group
Group type: EXPERIMENTAL
Intervention: Proguanil 100 mg BID plus sulfamethoxazole 1,000 mg BID for 7 days
Number of subjects: 25
Study 10347332 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg IV dofetilide over 30 minutes
Number of subjects: 96
Study 10347332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 10347332 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 micrograms/kg IV dofetilide
Number of subjects: 96
Study 7894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied twice daily for 16 days (phase 1)
Number of subjects: 12
Study 7894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 5th or 7th day (phase 2)
Number of subjects: 12
Study 7894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 10th day (phase 2)
Number of subjects: 12
Study 7894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasol propionate (CP) applied every 14th day (phase 2)
Number of subjects: 12
Study 7894098 — intervention group
Group type: EXPERIMENTAL
Intervention: Single application of Clobetasol propionate (CP)
Number of subjects: 12
Study 1657248 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin or low molecular weight heparin (LMWH; Fragmin)
Number of subjects: 194
Study 6406438 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (450 to 750 mg/day)
Number of subjects: 40
Study 6406438 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (75 to 225 mg/day)
Number of subjects: 40
Study 30308615 — intervention group
Group type: EXPERIMENTAL
Intervention: IBBR with ADM
Number of subjects: 135
Study 30308615 — intervention group
Group type: COMPARATOR
Intervention: IBBR without ADM
Number of subjects: 135
Study 28379650 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative eye patching for approximately 18 hours
Number of subjects: 132
Study 28379650 — intervention group
Group type: COMPARATOR
Intervention: Eye shield (control group)
Number of subjects: 132
Study 28379650 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative eye patching
Number of subjects: 132
Study 26370148 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation gaming device
Number of subjects: 15
Study 26370148 — intervention group
Group type: COMPARATOR
Intervention: Usual follow-up treatment
Number of subjects: 15
Study 24384803 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized counseling
Number of subjects: 240
Study 24384803 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control)
Number of subjects: 240
Study 24384803 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized counseling (among those with detectable virus at baseline)
Number of subjects: 240
Study 24384803 — intervention group
Group type: COMPARATOR
Intervention: Assessment only (Control) (among those with detectable virus at baseline)
Number of subjects: 240
Study 21992993 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% timolol maleate gel
Number of subjects: 43
Study 21992993 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol aqueous solution
Number of subjects: 43
Study 21992993 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate gel
Number of subjects: 43
Study 19357643 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4-diaminopyridine
Number of subjects: 9
Study 19357643 — intervention group
Group type: EXPERIMENTAL
Intervention: pyridostigmine
Number of subjects: 9
Study 19357643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 17473776 — intervention group
Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 81
Study 17473776 — intervention group
Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 81
Study 17473776 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study 17530933 — intervention group
Group type: EXPERIMENTAL
Intervention: HMB (3 g.d(‐1))
Number of subjects: 30
Study 17530933 — intervention group
Group type: EXPERIMENTAL
Intervention: HMBCr (12 g.d(‐1) with 3 g HMB, 3 g Cr, 6 g carbohydrates)
Number of subjects: 30
Study 17530933 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 15061303 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine 0.5 per cent
Number of subjects: 0
Study 15061303 — intervention group
Group type: COMPARATOR
Intervention: Preservative-free ketorolac tromethamine 0.5 per cent
Number of subjects: 0
Study 10962110 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial septal defect (ASD) group
Number of subjects: 21
Study 10962110 — intervention group
Group type: COMPARATOR
Intervention: Normal children
Number of subjects: 21
Study 9062158 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage chemotherapy and total parenteral nutrition (TPN)
Number of subjects: 21
Study 9062158 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy alone
Number of subjects: 21
Study 9062158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (unspecified)
Number of subjects: 21
Study 8458110 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose duteplase (0.16-0.29 MIU/kg)
Number of subjects: 75
Study 8458110 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle dose duteplase (0.30-0.41 MIU/kg)
Number of subjects: 75
Study 8458110 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose duteplase (0.43-0.74 MIU/kg)
Number of subjects: 75
Study 8458110 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of duteplase
Number of subjects: 75
Study 3463754 — intervention group
Group type: EXPERIMENTAL
Intervention: Premix (conventional alloy)
Number of subjects: 12
Study 3463754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersalloy (blended non-gamma 2 amalgam)
Number of subjects: 12
Study 3463754 — intervention group
Group type: EXPERIMENTAL
Intervention: Sybraloy (spherical alloy)
Number of subjects: 12
Study 3463754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tytin (spherical alloy)
Number of subjects: 12
Study 30321689 — intervention group
Group type: EXPERIMENTAL
Intervention: RT + 9 weekly cycles of docetaxel + 3 years of androgen deprivation therapy (arm B)
Number of subjects: 132
Study 30321689 — intervention group
Group type: COMPARATOR
Intervention: RT + 3 years of luteinizing hormone-releasing hormone analogues (arm A)
Number of subjects: 132
Study 27450646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesamin capsules; 200 mg/day
Number of subjects: 48
Study 27450646 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules; 200 mg/day starch
Number of subjects: 48
Study 25957183 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐intervention 1 (access to intervention during pregnancy and control at postpartum)
Number of subjects: 1722
Study 25957183 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐intervention 2 (access to intervention during pregnancy and postpartum)
Number of subjects: 1722
Study 25957183 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no intervention)
Number of subjects: 1722
Study 23423673 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa
Number of subjects: 20
Study 23423673 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 21106433 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental rotational grade V manipulation
Number of subjects: 50
Study 21106433 — intervention group
Group type: COMPARATOR
Intervention: McKenzie's lumbar extension exercises (EE)
Number of subjects: 50
Study 19410978 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg group (640 mg/d additional dietary cholesterol)
Number of subjects: 0
Study 19410978 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (0 mg/d additional dietary cholesterol)
Number of subjects: 0
Study 19410978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 16675507 — intervention group
Group type: EXPERIMENTAL
Intervention: Sparkling wine (30 g of ethanol/day for 28 days)
Number of subjects: 72
Study 16675507 — intervention group
Group type: EXPERIMENTAL
Intervention: White wine (20 g of ethanol/day for 28 days)
Number of subjects: 72
Study 16675507 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (20 g of ethanol/day for 28 days)
Number of subjects: 72
Study 16675507 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study on Mediterranean diet
Number of subjects: 72
Study 16675507 — intervention group
Group type: COMPARATOR
Intervention: Gin (30 g of ethanol/day for 28 days)
Number of subjects: 72
Study 15138203 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (single dose of 100 J/cm² at four hours) - PDT100 (n=13)
Number of subjects: 40
Study 15138203 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-PDT (fractionated dose of 20 and 100 J/cm² at one and four hours) - PDT20+100 (n=13)
Number of subjects: 40
Study 15138203 — intervention group
Group type: COMPARATOR
Intervention: Argon Plasma Coagulation (APC) at a power setting of 65 W in two sessions (n=14)
Number of subjects: 40
Study 15138203 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination at 12 months for PDT100 (n=11)
Number of subjects: 40
Study 15138203 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological examination at 12 months for PDT20+100 (n=10)
Number of subjects: 40
Study 15138203 — intervention group
Group type: COMPARATOR
Intervention: Histological examination at 12 months for APC (n=12)
Number of subjects: 40
Study 15138203 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects after PDT
Number of subjects: 40
Study 11479245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/bendrofluazide
Number of subjects: 12
Study 11479245 — intervention group
Group type: COMPARATOR
Intervention: Atenolol/bendrofluazide
Number of subjects: 12
Study 11479245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol/bendrofluazide and Atenolol/bendrofluazide
Number of subjects: 12
Study 9757191 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative chemotherapy and pre-operative induction chemotherapy in patients with stage IIIA N2 disease
Number of subjects: 0
Study 9757191 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with thoracic radiotherapy (TRT) in unresectable, locally advanced NSCLC
Number of subjects: 0
Study 9757191 — intervention group
Group type: EXPERIMENTAL
Intervention: Timely combination of TRT and chemotherapy
Number of subjects: 0
Study 9757191 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapeutic agents as radiosensitizers
Number of subjects: 0
Study 9757191 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of TRT and new agents in unresectable, locally advanced NSCLC
Number of subjects: 0